| PubMed |
Abstract |
RScore(About this table) |
| 19820023 |
Tacon LJ, Soon PS, Gill AJ, Chou AS, Clarkson A, Botling J, Stalberg PL, Skogseid BM, Robinson BG, Sidhu SB, Clifton-Bligh RJ: The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J Clin Endocrinol Metab. 2009 Nov;94(11):4591-9. Epub 2009 Oct 9.
|
3(0,0,0,3) |
Details |
| 19673019 |
Sanchez R, Levy E, Costea F, Sinnett D: IL-10 and TNF-alpha promoter haplotypes are associated with childhood Crohn's disease location. World J Gastroenterol. 2009 Aug 14;15(30):3776-82.
AIM: To determine the distribution and frequencies of the genotypes and haplotypes of the genes encoding for the glucocorticoid receptor (GR), the tumor necrosis factor (TNF)-alpha and the interleukin (IL)-10 in childhood Crohn's disease (CD) and to assess the impact of the corresponding DNA variants on clinical and disease phenotypes. |
1(0,0,0,1) |
Details |
| 17391151 |
Clapham JC, Arch JR: Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab. 2007 May;9(3):259-75.
Some thermogenic approaches are the activation of adrenergic, thyroid hormone or growth hormone receptors and the inhibition of glucocorticoid receptors; the modulation of transcription factors [e.g. peroxisome proliferator-activated receptor delta (PPARdelta) activators] or enzymes [e.g. glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors] that promote mitochondrial biogenesis, and the modulation of transcription factors (PPAR alpha activators) or enzymes (AMP-activated protein kinase) that promote fatty acid oxidation. |
1(0,0,0,1) |
Details |